TBPH · CIK 0001583107
What Theravance Biopharma, Inc. told the SEC could break it.
Theravance's disclosures describe a company riding almost entirely on a single drug, YUPELRI. Every link in that product's chain is single-threaded — one supplier of its active ingredient, one of finished drug product, and a single warehouse — and its revenue is just as concentrated: the Viatris collaboration that commercializes YUPELRI was 100% of total revenue ($75.0 million) in 2025. Its main bid to broaden beyond YUPELRI faltered when the CYPRESS trial of ampreloxetine missed its primary endpoint in March 2026, prompting a restructuring, even as YUPELRI's Medicare reimbursement leaves it exposed to IRA drug-pricing changes, including a new 10% Part D manufacturer discount.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- single-source YUPELRI API, drug product & warehousehigh
YUPELRI's supply chain is entirely single-threaded — one supplier of API, one supplier of drug product, and a single warehousing facility — so any disruption could harm Theravance's business with no ready alternative.
“There is a single supplier of YUPELRI API, a single supplier of YUPELRI drug product and YUPELRI is warehoused in a single facility.”
SEC filing →As of 2026
Customer concentration
- Viatris = 100% of total revenuemedium
Theravance's revenue comes essentially entirely from its Viatris collaboration (Viatris was 100% of total revenue in 2025 and 2024) — $75.0M in 2025 — so the relationship and YUPELRI's commercial performance fully determine its top line.
“In 2025 and 2024, we recognized $75.0 million and $64.4 million, respectively, in revenue from the Viatris collaboration agreement, which represented an increase of 16%.”
SEC filing →As of 2026
Other disclosures
- ampreloxetine CYPRESS trial failure / pipeline reliancemedium
Theravance's pipeline beyond YUPELRI suffered a setback — the CYPRESS study of ampreloxetine missed its primary endpoint (announced March 3, 2026), undermining a key royalty-backed asset and prompting a March 2026 organizational restructuring.
“On March 3, 2026, we announced that the CYPRESS study did not meet its primary endpoint in the OHSA composite score.”
SEC filing →As of 2026
Regulatory & policy
- IRA Medicare drug-pricing (Part D manufacturer discount)medium
YUPELRI is reimbursed under Medicare, exposing Theravance/Viatris to IRA drug-pricing changes — the sunset of the coverage-gap discount program (2025) and a new manufacturer discount program requiring a 10% Part D discount in the initial coverage phase.
“A new manufacturer discount program replaced the previous program, requiring manufacturers to provide a 10% discount on a covered Part D drug where a beneficiary is in the initial phase of Part D coverage”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“In the US, Viatris is leading the commercialization of YUPELRI, and we co-promote the product under a profit and loss sharing arrangement (65% to Viatris; 35% to us).”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch